Core Insights - GlobalFoundries has filed multiple patent lawsuits against Tower Semiconductor, alleging infringement of 11 patents related to manufacturing process technologies [8] - The lawsuits aim to prevent Tower from importing and selling products that allegedly violate GlobalFoundries' patents [8] - GlobalFoundries claims that Tower unlawfully used its protected technologies in the production of semiconductors for various sectors, including smart mobile, automotive, and aerospace [3] Company Background - GlobalFoundries was established in 2009 as a chipmaking offshoot of AMD and acquired IBM's microelectronics facilities in 2015, along with thousands of IBM patents [6] - The company reported fourth-quarter revenue of $1.83 billion, driven by demand in artificial intelligence and data centers [6] - GlobalFoundries holds over 8,000 patents, a result of billions of dollars invested over the past decade, while Tower Semiconductor has less than 500 patents [7] Legal Context - The patents in question range from a "high voltage device" to a "self-aligned liner formed on metal semiconductor alloy contacts" [4] - GlobalFoundries is seeking compensation for lost profits due to the alleged infringement [7] - A spokesperson for Tower Semiconductor has denied the allegations and stated that the company will defend itself in court [8]

Core Viewpoint - The U.S. District Court for the District of Delaware upheld the jury's finding of willful infringement by Alcon and awarded Sight Sciences over $34 million in past damages, along with ongoing royalties through November 2028 [1][2]. Legal Outcome - The Court's order confirmed the jury's verdict that Alcon willfully infringed all three of Sight Sciences' asserted patents and awarded $34 million in monetary damages, which includes $5.5 million in lost profits and $28.5 million in royalty damages [2][6]. - An ongoing royalty of 10% of Hydrus revenue will be applicable until the expiration of Sight Sciences' last asserted patent on November 10, 2028 [2][6]. Company Perspective - Sight Sciences expressed satisfaction with the ruling, emphasizing the importance of its intellectual property portfolio in interventional glaucoma and its commitment to advancing glaucoma care through innovative technologies [4]. - The company anticipates recording a $5.4 million success fee related to the litigation, which will be excluded from non-GAAP adjusted operating expenses [4]. Product and Technology Focus - Sight Sciences is dedicated to developing innovative and interventional solutions for eye care, particularly in the field of glaucoma, utilizing minimally invasive techniques [5]. - The company's products include the OMNI® Surgical System and OMNI® Edge Surgical System, which are designed to reduce intraocular pressure in patients with primary open-angle glaucoma [5].

Group 1 - Alpha Modus (AMOD) has resolved its patent infringement litigation against Brookshire Grocery Co. in the United States District Court for the Eastern District of Texas [1] - The litigation involved allegations related to Alpha Modus's patented technologies, which include real-time consumer behavior analysis, digital advertising systems, smart retail display technologies, and AI-driven in-store engagement platforms [1] - All claims between Alpha Modus and Brookshire Grocery Co. have been resolved, and both parties have moved for dismissal of the litigation with prejudice [1]

Core Viewpoint - Xeris Biopharma Holdings, Inc. is facing a decline in stock price following the announcement of a patent infringement lawsuit aimed at protecting its drug, Recorlev [1] Group 1: Lawsuit Details - The lawsuit targets Torrent Pharmaceuticals Limited and Somerset Therapeutics, LLC for attempting to produce unauthorized generic versions of Recorlev [2] - Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited are the plaintiffs in this case, emphasizing their commitment to defend their intellectual property until March 2040, supported by Orphan Drug Exclusivity until December 2028 [3] Group 2: Stock Performance - Despite a 61.30% increase in stock price over the past year, Xeris Biopharma's shares are currently trading below key moving averages, indicating a bearish outlook [4] - The stock is 12.6% below the 20-day SMA, 15.9% below the 50-day SMA, and 20.2% below the 100-day SMA, suggesting caution among investors [4] Group 3: Technical Indicators - The Relative Strength Index (RSI) is at 42.31, indicating a lack of strong momentum, while the MACD is positioned below the signal line, reinforcing bearish trends [5] Group 4: Earnings & Analyst Outlook - Xeris Biopharma is set to report earnings on March 2, 2026, with analysts expecting an EPS of 4 cents and revenue of $84.17 million, up from a loss of 3 cents and $60.10 million YoY respectively [6][7] - The stock currently holds a Buy Rating with an average price target of $11.03, with various analysts maintaining or initiating targets ranging from $9.00 to $18.00 [6][7]

Bloomberg News Health Reporter Madison Muller reports on the latest on Novo's lawsuit. - Novo Nordisk said it’s suing Hims & Hers Health Inc. for making knock-offs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill. Hims is breaching the US patent on semaglutide, the active ingredient in Novo’s blockbuster obesity treatments, Novo argued Monday. The US lawsuit attacks not only Hims’ new strategy to launch a copycat pill but also goes after shots that mimic Weg ...

Let's begin with Novo Nordisk suing hims and hers, accusing the telehealth firm of infringing its U.S. patent on key ingredient in its epic. And we go by. Let's get the latest.The same for he's the senior pharmaceutical analyst at Bloomberg Intelligence. Sam, we were just talking on Friday and you were telling us there is a danger to this. This isn't good.It sounds like hims and hers has finally listened to some of the criticism and threats coming from regulators. Yeah, well, Daddy, the point here is not ab ...

Core Viewpoint - Moderna is facing a $5 billion patent-infringement lawsuit regarding its COVID-19 vaccine, Spikevax, which allegedly infringes on lipid nanoparticle technology patented by Genevant Sciences and Arbutus Biopharma [1]. Legal Proceedings - U.S. District Judge Joshua D. Wolson denied Moderna's request for summary judgment, allowing the jury to decide on the patent infringement claims [1]. - The judge emphasized the importance of patent law, stating that copying inventions is not permissible, even with expedited vaccine development under "Operation Warp Speed" [2]. Technical Aspects of the Case - The lawsuit centers on the delivery mechanism of the vaccine, specifically how Messenger RNA (mRNA) is protected by lipid nanoparticles, which are claimed to be patented by the plaintiffs [3]. - Arbutus Biopharma asserts that their research involved identifying specific "molar ratios" of lipids necessary for the vaccine's safety and efficacy [3]. Government Immunity Defense - Moderna's defense strategy included invoking section 1498, which protects government contractors from patent infringement lawsuits, arguing that the vaccine was developed under a federal program [4]. - However, the judge ruled that section 1498 applies only if the product was intended for the government itself, not the general public, which could expose Moderna to $5 billion in damages [5]. Patent Validity and Infringement - The jury will also evaluate the scientific validity of the patent claims and the concept of "literal infringement," with the judge allowing certain technical requests regarding how patent infringement can be established [6].

Core Viewpoint - Meta Platforms Inc. is facing a patent infringement lawsuit from Solos Technology Ltd., which also targets EssilorLuxottica SA and its Oakley subsidiary, over alleged violations related to smart eyewear technologies [1][2]. Group 1: Lawsuit Details - Solos Technology Ltd. filed a complaint in a federal Massachusetts court, accusing Meta and others of willfully infringing on several patents related to smart eyewear technologies [2]. - The lawsuit seeks "multiple billions of dollars" in damages and an injunction that could disrupt sales of Ray-Ban Meta products [2]. - The infringement claim primarily focuses on the Ray-Ban Meta Wayfarer Gen 1, asserting that subsequent releases continue to infringe on Solos' patented technologies [5]. Group 2: Background on Solos Technology - Solos has a history in smart eyewear, initially targeting cyclists, and has developed models like the "AirGo" series with AI features [4]. - The company claims to have an intellectual property portfolio of over 100 patents and applications [4]. - Solos alleges that Oakley employees were introduced to its technology as early as 2015, and that EssilorLuxottica gained insights into Solos' concepts during meetings in 2017 [5]. Group 3: Meta's Position and Market Context - Meta is also facing a separate patent infringement suit regarding the muscle-signal technology used in its Ray-Ban Display glasses [3]. - The collaboration between Meta and EssilorLuxottica on smart glasses began around 2021, with both companies having accumulated detailed knowledge of Solos' technology prior to commercialization [7]. - Despite Solos' challenges in the consumer market, the Ray-Ban Meta portfolio has received positive customer feedback, and Meta and EssilorLuxottica are considering doubling their manufacturing output to meet demand [8].

Core Viewpoint - Meta Platforms Inc. and EssilorLuxottica SA are facing a lawsuit from Solos Technology Ltd. over allegations of patent infringement related to smart glasses [2] Company Summary - Solos Technology Ltd. has filed a complaint against Meta Platforms Inc. and EssilorLuxottica SA, claiming that their smart glasses infringe on its patents [2]

Core Viewpoint - Masimo Corp. achieved a significant legal victory against Apple Inc. with a $634 million judgment, yet its underlying fundamentals indicate potential weaknesses in operational efficiency and financial health [1][6]. Fundamentals Under Pressure - Masimo's quality score has decreased to 10.43, placing it in the bottom tier of stocks for operational efficiency, indicating underperformance compared to nearly 90% of the market [2][3]. - The company's core operational metrics and historical profitability remain weak relative to industry competitors, despite the cash influx from the lawsuit [3]. Technical Indicators - The stock's momentum score is low at 8.77, reflecting weak relative strength and price movement patterns compared to other stocks [4]. - Masimo's stock is experiencing a downward trend across short, medium, and long timeframes, indicating persistent selling pressure over the past year [5]. Legal Victory - A federal jury in California ruled that Apple infringed on Masimo's blood-oxygen sensor patents, resulting in a $634 million award to Masimo, which the company views as a significant win for its innovation efforts [6]. Stock Performance - In 2025, Masimo's shares dropped by 22.85%, underperforming against the Nasdaq Composite index, which gained 20.54% during the same period [7]. - Over the last six months, the stock fell by 24.09%, closing the last trading day of 2025 at $130.06, with no change in pre-market trading [7].